Pfizer (PFE) AI Stock Analysis

Pfizer

(BMV:PFE)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Launched and acquired product growthStrong growth from launched and acquired products shows Pfizer is rebuilding its commercial base beyond legacy and COVID products. Expanding contributions from Seagen assets and other brands can support more durable revenue growth, improve portfolio mix, and help offset future patent-related declines.

Negative Factors

Elevated leverage during the LOE transitionLeverage near 2.7x limits financial flexibility as Pfizer faces upcoming loss-of-exclusivity events and continued investment needs. If cash flow weakens during the transition, a heavier debt burden could constrain acquisitions, research spending, shareholder returns, and the pace of portfolio renewal.

Pfizer (PFE) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 173.95B
Dividend Yield: 5.27%
Average Volume (3M): 2,699
Price to Earnings (P/E): 40.3
Beta (1Y): 0.10
Revenue Growth: -8.84%
EPS Growth: -62.56%
Country: Mexico
Employees: 75,000
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - General

Pfizer Business Overview & Revenue Model

Company Description

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic area...

Pfizer Earnings Call Summary

Earnings Call Date:Aug 03, 2026(Q2-2026)|% Change Since:31.49%|Next Earnings Date:Nov 02, 2026

Earnings Call SentimentPositive

The call conveyed a generally positive operational and strategic narrative: management beat Q2 revenue and adjusted EPS expectations, raised full-year revenue guidance, highlighted strong growth across launched and acquired products (notably Seagen assets, Padcev, NURTEC, and Eliquis), and outlined robust R&D progress (numerous readouts, pivotal starts and promising clinical data across obesity, oncology and immunology). At the same time, material near-term setbacks were disclosed: a Phase III SV miss that drove a $4.3 billion impairment and a GAAP loss, lower-than-expected COVID revenues (notably Paxlovid), removal of Oxbryta revenue from forecasts, and elevated near-term R&D spend. Management emphasized cost-savings initiatives (now targeting ~ $9.7B through 2029), maintained dividend commitments, and raised confidence in returning to growth by the end of the decade. Overall, positives (revenue/EPS beats, guidance raise, strong launched/acquired product growth, and significant pipeline progress) outweigh the material but specific negatives tied largely to one clinical readout and COVID variability.

Positive Updates

Quarterly Revenue and Underlying Growth

Total Q2 2026 revenue of $15.0 billion, a 1% year-over-year operational increase. Excluding COVID products, the underlying business grew 5% operationally.

Negative Updates

SV Phase III Miss and Large Impairment Charge

Primary overall survival endpoint not met in the ITT population for the SV non-squamous NSCLC Phase III readout. Q2 GAAP results included $4.3 billion in noncash intangible asset impairments (partly tied to the SV readout and removal of Oxbryta revenue projection). Reported GAAP loss per share was -$0.04 for the quarter.

Company Guidance

Pfizer raised full‑year 2026 revenue guidance to $60.5–$62.5 billion (midpoint up $0.5B) and reaffirmed adjusted diluted EPS of $2.80–$3.00 (which absorbs an ~ $0.10 headwind tied to a $650M acquired IPR&D charge), while trimming 2026 COVID revenue to ~ $4B (from $5B). Management expects adjusted gross margin in the mid‑70s (Q2 was 76%), and Q2 results included $15B revenue (+1% operational; +5% ex‑COVID), $0.77 adjusted diluted EPS (reported loss per share –$0.04), $3.2B in launched/acquired product revenue (up 18% operational; 27% ex‑one‑time items), 35% adjusted operating margin, $6.1B adjusted operating expenses (R&D +12% op, SG&A –3% op), $3.45B operating cash flow and 2.7x leverage. Pfizer reiterated productivity targets — $700M of Phase‑1 manufacturing savings in 2026 (with $175M realized in Q2), remains on track for most of $7.2B in net savings by end‑2026, and expanded programs to target roughly $9.7B of total net savings through 2029 (including ~ $3B from manufacturing optimization).

Pfizer Risk Analysis

Pfizer disclosed 26 risk factors in its most recent earnings report. Pfizer reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks

1.We have expended and will continue to expend significant time and resources in connection with the acquisition of Seagen and have incurred substantial indebtedness to fund the acquisition.Q3, 2023

2.We may not be successful in identifying and executing potential business development transactions, such as our acquisition of Seagen, or realizing the financial and strategic goals that were contemplated at the time of any historical or potential business development transaction, which could have an adverse impact on our ability to meet our growth objectives.Q3, 2023

3.We may be unable to complete the acquisition of Seagen within the anticipated timeframe or at all, which could prevent us from receiving the anticipated benefits from the acquisition in the anticipated timeframe or at all.Q3, 2023

Pfizer Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:PFE against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LLY	81Outperform	$1.33T	45.89	83.65%	0.47%	45.51%	50.48%
ABBV	72Outperform	$521.11B	83.08	-223.75%	2.35%	10.68%	―
NVS	72Outperform	$297.25B	31.19	24.24%	2.95%	1.64%	-28.72%
JNJ	70Outperform	$657.68B	41.42	19.55%	1.93%	7.81%	-35.95%
MRK	63Neutral	$368.89B	152.57	5.10%	2.27%	5.16%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

MX:PFE and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:PFE	Pfizer Inc	572.00	145.23	34.03%
LLY	Eli Lilly And Company	1417.54	526.63	59.11%
JNJ	Johnson & Johnson	273.20	91.04	49.98%
MRK	Merck & Company	149.52	69.38	86.58%
NVS	Novartis AG	160.79	39.31	32.36%
ABBV	Abbvie	294.89	89.09	43.29%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Pfizer AI Stock Analysis